Credence

Microemulsion Foam Offers New Approach to Topical Pain Medication Delivery


Key Points

  • University of Alberta researchers developed FoamaDerm, a microemulsion foam that delivers diclofenac effectively at just 2%
  • Studies found FoamaDerm delivered approximately twice as much active ingredient as competing products
  • RS Therapeutics supplies FoamaDerm to pharmacies across Canada and is working toward introducing it to the U.S. market

Researchers at the University of Alberta have developed a topical drug delivery formulation that could improve the effectiveness of pain medications used to treat chronic conditions such as arthritis. The technology, marketed as FoamaDerm, uses a microemulsion-based foam to deliver diclofenac through the skin more efficiently than conventional creams and ointments, while also simplifying the compounding process for pharmacists.

Traditional compounded topical non-steroidal anti-inflammatory drugs (NSAIDs), including diclofenac, often contain concentrations of 5% to 10% or higher. However, research conducted by the University of Alberta team found that many existing formulations do not adequately release their active ingredients. FoamaDerm, by comparison, has demonstrated effective drug delivery at a concentration of just 2%.

The formulation was developed at the university’s Drug Development and Innovation Center (DDIC), led by Dr. Raimar Löbenberg, a professor in the Faculty of Pharmacy and Pharmaceutical Sciences. The project began after an insurance company approached the research team with questions about the performance of compounded diclofenac products compared with commercially available alternatives.

Löbenberg and his colleagues investigated whether a microemulsion could improve drug release and skin penetration. Their studies found that the formulation delivered approximately twice as much active ingredient as competing products.

Topical NSAIDs are frequently prescribed as an alternative to oral pain medications, particularly for patients who may be at risk of gastrointestinal complications associated with oral NSAID use. FoamaDerm is formulated as a clear liquid containing water and coconut oil. Its microemulsion structure is designed to help diclofenac pass through the stratum corneum, the skin’s outermost protective barrier.

A propellant-free pump converts the liquid into a foam for application. Once rubbed into the skin, the foam disappears without leaving a noticeable residue on skin or clothing.

The technology has moved beyond the university laboratory through RS Therapeutics Inc., a company established by Löbenberg and his colleagues. The company currently supplies FoamaDerm as a compounding base to pharmacies across Canada and has established a laboratory in North Carolina as it works toward introducing the product to the U.S. market.

In addition to its drug delivery performance, the formulation offers a simpler preparation process for compounding pharmacies. Pharmacists can dissolve the active ingredient directly into the microemulsion within minutes, eliminating the need for solvents, grinding procedures or specialized compounding equipment.

Löbenberg said the team has received positive feedback from Canadian pharmacies reporting that they have transitioned patients to the foam formulation.

FoamaDerm is one example of the broader formulation and drug delivery research underway at the DDIC. Löbenberg established the center in 2009 to address a common challenge in pharmaceutical development: determining how best to deliver a drug after its active ingredient has been identified.

The center works with academic researchers, emerging biotechnology companies and established pharmaceutical manufacturers on a range of formulation and delivery projects. Its research has included vitamin supplements, medical cannabis formulations and nanoparticle-based powders designed to transport cancer therapeutics directly to the lungs.

Other areas of investigation include oral thin films for precise drug dosing, delivery of cancer therapies through the lymphatic system and dissolution testing to better predict how tablets and capsules behave in the gastrointestinal tract. Löbenberg also chairs a committee for the United States Pharmacopeia, which develops standards for medicines and pharmaceutical ingredients.

The research team plans to continue evaluating FoamaDerm as a potential delivery vehicle for additional active pharmaceutical ingredients beyond diclofenac. Its microemulsion technology could offer opportunities for other topical therapies where improving skin penetration and drug release is important.

As Löbenberg’s work demonstrates, selecting the right delivery system can be just as important as developing the drug itself. By tailoring formulations to the intended site of administration, researchers hope to improve drug performance and expand options for patients across a range of therapeutic areas.

Learn more at www.ualberta.ca.